FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2057180889> ?p ?o ?g. }

• W2057180889 endingPage "236" @default.
• W2057180889 startingPage "231" @default.
• W2057180889 abstract "HER2 is reported to be overexpressed in 20% of cases of non-small-cell lung cancer (NSCLC), principally adenocarcinoma. Trastuzumab is a monoclonal antibody against HER2 that, when combined with a taxane, improves survival compared with chemotherapy alone in advanced breast cancer. In view of these observations, we conducted a phase II HER2 screening and efficacy trial of trastuzumab plus weekly docetaxel in cases of advanced NSCLC in which primary platinum-based therapy had failed. Patients with advanced or metastatic NSCLC were screened for HER2 overexpression by immunohistochemistry. Patients with HER2-positive tumors (2+ or 3+) were initially randomized to either single-agent trastuzumab or docetaxel. After completing 2 treatment cycles, all patients went on to receive the trastuzumab/docetaxel combination regardless of response to the single agents. Treatment consisted of docetaxel 30 mg/m2 weekly for 6 weeks followed by a 2-week break and trastuzumab 4 mg/kg intravenously on week 1 followed by 2 mg/kg per week thereafter. Cycle length was 8 weeks. Sixty-nine patients with NSCLC (33 men, 36 women) were screened between August 1999 and March 2001. Only 13 patients (19%) had HER2-positive disease; all 13 enrolled in the efficacy trial. Of 9 patients receiving docetaxel alone, 1 partial response (PR) was seen. None responded to trastuzumab alone. The overall outcomes to the sequence of single-agent therapy followed by combination therapy included a PR rate in 8% of cases, stable disease in 23%, progression in 46%, and nonassessable disease in 23%. Estimated event-free and overall survival times were 4.3 and 5.7 months, respectively. Treatment was well tolerated. The screening component of this trial demonstrated that the target population for trastuzumab therapy in NSCLC is relatively small. Because of the limited clinical activity of trastuzumab-based therapy in this cohort and the similar disappointing reports from other studies of trastuzumab in NSCLC, this trial was closed to further accrual. In view of the limited target population for HER2 inhibition, future efforts and resources should be directed toward molecular targets other than HER2 in NSCLC." @default.
• W2057180889 created "2016-06-24" @default.
• W2057180889 creator A5021148471 @default.
• W2057180889 creator A5036091074 @default.
• W2057180889 creator A5041200743 @default.
• W2057180889 creator A5054519317 @default.
• W2057180889 creator A5061039184 @default.
• W2057180889 creator A5070878175 @default.
• W2057180889 creator A5075799959 @default.
• W2057180889 creator A5086089087 @default.
• W2057180889 date "2004-01-01" @default.
• W2057180889 modified "2023-10-04" @default.
• W2057180889 title "Trastuzumab plus Docetaxel in HER2/neu–Positive Non–Small-Cell Lung Cancer: A California Cancer Consortium Screening and Phase II Trial" @default.
• W2057180889 cites W1867197625 @default.
• W2057180889 cites W1970019155 @default.
• W2057180889 cites W2059031630 @default.
• W2057180889 cites W2074725242 @default.
• W2057180889 cites W2091033650 @default.
• W2057180889 cites W2092429540 @default.
• W2057180889 cites W2093802595 @default.
• W2057180889 cites W2095156669 @default.
• W2057180889 cites W2127268764 @default.
• W2057180889 cites W2130652363 @default.
• W2057180889 cites W2199607744 @default.
• W2057180889 cites W2276418696 @default.
• W2057180889 cites W2318605753 @default.
• W2057180889 cites W3022296611 @default.
• W2057180889 doi "https://doi.org/10.3816/clc.2004.n.004" @default.
• W2057180889 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14967075" @default.
• W2057180889 hasPublicationYear "2004" @default.
• W2057180889 type Work @default.
• W2057180889 sameAs 2057180889 @default.
• W2057180889 citedByCount "93" @default.
• W2057180889 countsByYear W20571808892012 @default.
• W2057180889 countsByYear W20571808892013 @default.
• W2057180889 countsByYear W20571808892014 @default.
• W2057180889 countsByYear W20571808892015 @default.
• W2057180889 countsByYear W20571808892016 @default.
• W2057180889 countsByYear W20571808892017 @default.
• W2057180889 countsByYear W20571808892018 @default.
• W2057180889 countsByYear W20571808892019 @default.
• W2057180889 countsByYear W20571808892020 @default.
• W2057180889 countsByYear W20571808892021 @default.
• W2057180889 countsByYear W20571808892022 @default.
• W2057180889 countsByYear W20571808892023 @default.
• W2057180889 crossrefType "journal-article" @default.
• W2057180889 hasAuthorship W2057180889A5021148471 @default.
• W2057180889 hasAuthorship W2057180889A5036091074 @default.
• W2057180889 hasAuthorship W2057180889A5041200743 @default.
• W2057180889 hasAuthorship W2057180889A5054519317 @default.
• W2057180889 hasAuthorship W2057180889A5061039184 @default.
• W2057180889 hasAuthorship W2057180889A5070878175 @default.
• W2057180889 hasAuthorship W2057180889A5075799959 @default.
• W2057180889 hasAuthorship W2057180889A5086089087 @default.
• W2057180889 hasConcept C121608353 @default.
• W2057180889 hasConcept C126322002 @default.
• W2057180889 hasConcept C143998085 @default.
• W2057180889 hasConcept C2776256026 @default.
• W2057180889 hasConcept C2776694085 @default.
• W2057180889 hasConcept C2777511904 @default.
• W2057180889 hasConcept C2778822529 @default.
• W2057180889 hasConcept C2779786085 @default.
• W2057180889 hasConcept C2781190966 @default.
• W2057180889 hasConcept C530470458 @default.
• W2057180889 hasConcept C71924100 @default.
• W2057180889 hasConceptScore W2057180889C121608353 @default.
• W2057180889 hasConceptScore W2057180889C126322002 @default.
• W2057180889 hasConceptScore W2057180889C143998085 @default.
• W2057180889 hasConceptScore W2057180889C2776256026 @default.
• W2057180889 hasConceptScore W2057180889C2776694085 @default.
• W2057180889 hasConceptScore W2057180889C2777511904 @default.
• W2057180889 hasConceptScore W2057180889C2778822529 @default.
• W2057180889 hasConceptScore W2057180889C2779786085 @default.
• W2057180889 hasConceptScore W2057180889C2781190966 @default.
• W2057180889 hasConceptScore W2057180889C530470458 @default.
• W2057180889 hasConceptScore W2057180889C71924100 @default.
• W2057180889 hasIssue "4" @default.
• W2057180889 hasLocation W20571808891 @default.
• W2057180889 hasLocation W20571808892 @default.
• W2057180889 hasOpenAccess W2057180889 @default.
• W2057180889 hasPrimaryLocation W20571808891 @default.
• W2057180889 hasRelatedWork W1961616138 @default.
• W2057180889 hasRelatedWork W1971716849 @default.
• W2057180889 hasRelatedWork W2014205823 @default.
• W2057180889 hasRelatedWork W2018426258 @default.
• W2057180889 hasRelatedWork W2057180889 @default.
• W2057180889 hasRelatedWork W2085844047 @default.
• W2057180889 hasRelatedWork W2091007248 @default.
• W2057180889 hasRelatedWork W2143637725 @default.
• W2057180889 hasRelatedWork W2394860297 @default.
• W2057180889 hasRelatedWork W4300176258 @default.
• W2057180889 hasVolume "5" @default.
• W2057180889 isParatext "false" @default.
• W2057180889 isRetracted "false" @default.
• W2057180889 magId "2057180889" @default.
• W2057180889 workType "article" @default.